Coherus Oncology to Present Innovative Cancer Research at SITC
Coherus Oncology's Groundbreaking Presentation at SITC
Coherus Oncology, Inc. (NASDAQ: CHRS), recognized for its commitment to advancing cancer treatment, has exciting news! An engaging poster presentation is scheduled for the upcoming 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 5 to 9, 2025. This event promises to be a significant gathering for leaders in the field of immunotherapy.
Details of the Presentation
During this event, Coherus will present an abstract titled, CHS-114: An anti-CCR8 cytolytic monoclonal antibody demonstrates selective intratumoral Treg depletion and favorable immune remodeling in participants with advanced solid tumors. This research highlights promising results regarding the efficacy of CHS-114 in improving treatment outcomes for patients with hard-to-treat tumors.
Presentation Schedule
The presentation is set for Saturday, November 8, 2025, at the Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center. This platform will allow researchers and clinicians to engage with the findings and explore the implications for future cancer therapies.
Webinar Series Featuring Novel Therapeutics
In addition to the poster presentation, Coherus is part of the webinar series titled Targets for Cancer IO: A Deep Dive. The next session, focusing on the Development of Anti-CCR8 Ab - Mechanisms and Clinical Results, will occur on October 22, 2025, from 12:00 to 2:00 PM Eastern Time. This webinar is a fantastic opportunity for professionals to dive deep into the role of the C-C chemokine receptor 8 (CCR8) in immunological responses.
Webinar Insights
The webinar will be moderated by Enrico Lugli, PhD, from the Humanitas Research Hospital, and Rahul Roychoudhuri, MD, PhD, from the University of Cambridge. Guest faculty includes Rosh Dias, MD, MRCP, and Varun Kapoor, PhD, from Coherus Oncology, as well as Jo Van Ginderachter, PhD, from Vrije Universiteit Brussel. This lineup represents a formidable collection of expertise aimed at advancing cancer treatment.
About Coherus Oncology
Coherus Oncology stands out as a leading commercial-stage biotechnology company, particularly known for its innovative PD-1 inhibitor, LOQTORZI (toripalimab-tpzi). The company not only boasts impressive revenues but also maintains a robust pipeline of treatments currently in mid-stage clinical trials targeting various cancer types, including liver, lung, head and neck, and colorectal cancers.
Innovative Pipeline Development
Central to Coherus' commitment is its immuno-oncology pipeline, which focuses on advanced antibody therapies designed to enhance both innate and adaptive immune responses. One notable candidate, Casdozokitug, is an IL-27 antagonistic antibody now undergoing evaluation in several Phase 1/2 and Phase 2 studies for patients grappling with advanced solid tumors.
Ongoing Clinical Trials and Research
Moreover, CHS-114, the antibody being presented at SITC, is currently in Phase 1b/2a studies across a spectrum of advanced solid tumors. These trials have taken aim at malignancies that typically present substantial treatment challenges, including head and neck, colorectal, gastric, and esophageal cancers.
Contact Coherus Oncology
For investors and interested parties, Coherus encourages further engagement. Please contact Jodi Sievers, VP of Investor Relations & Corporate Communications, at: IR@coherus.com for more detailed information.
Frequently Asked Questions
What is the significance of the SITC meeting?
The SITC meeting showcases groundbreaking research and developments in cancer immunotherapy, offering a platform for experts to discuss advancements.
When is Coherus' poster presentation scheduled?
The presentation is scheduled for November 8, 2025, at the Prince George ABC Exhibit Halls.
What is CHS-114?
CHS-114 is an anti-CCR8 monoclonal antibody aimed at enhancing treatment responses in patients with advanced solid tumors.
How can one register for the webinar?
Details to register for the webinar series are available on the SITC website.
What types of cancers are part of Coherus' research?
Coherus' research encompasses various cancers, including liver, lung, head and neck, colorectal, gastric, and esophageal cancers.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
